Clinical Trials on AML

Total 431746 results

Samsung Medical Center

Unknown

Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI)

Lymphoma | AML | MDS | CML | ALL

Korea, Republic of
Abramson Cancer Center of the University of Pennsylvania

Completed

Sirolimus in Combination With MEC in High Risk Myeloid Leukemias (UPCC 02407)

Leukemia | AML | CML | Myeloid Leukemias

United States
Cytheris, Inc.

Completed

Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant

AML | MDS | CML

United States
Synta Pharmaceuticals Corp.

Completed

STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders

Myeloproliferative Disorders | AML | MDS | CML

United States
Daiichi Sankyo Co., Ltd.

Completed

Phase 1 Study of Quizartinib

Relapsed AML | Refractory AML

Japan
Carbiogene Therapeutics Co. Ltd.
Zhejiang Provincial People's Hospital

Recruiting

Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5)

AML M5 | AML M4

China
DKMS gemeinnützige GmbH

Active, not recruiting

Haploidentical Donor vs mMUD in Hematological Malignancies (HAMLET)

AML | MDS | ALL

Germany
University of Alabama at Birmingham

Not yet recruiting

CD34 Selection Using the Automated CliniMACS Prodigy

Myelodysplastic Syndromes | Primary Myelofibrosis | AML | Lymphoid Malignancies | CML | ALL

United States
Zhejiang University

Not yet recruiting

Evaluate the Safety and Efficacy of CD33 CAR-T in Patients With R/R AML

AML

China
Zhejiang University

Not yet recruiting

Evaluate the Safety and Efficacy of CLL1 CAR-T in Patients With R/R AML

AML

China
Zhejiang University

Not yet recruiting

Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML

AML

China
Zhejiang University

Not yet recruiting

Evaluate the Safety and Efficacy of ADGRE2 CAR-T in Patients With R/R AML

AML

China
Aptevo Therapeutics

Withdrawn

Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML

AML
Martin-Luther-Universität Halle-Wittenberg

Unknown

Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible (TCP-AML)

AML

Germany
Nantes University Hospital

Completed

High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML)

AML

France
PETHEMA Foundation

Recruiting

Epidemiologic Registry PETHEMA LMA 2015

AML

Spain
Hospital Universitario Dr. Jose E. Gonzalez

Completed

Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML

AML

Mexico
Rambam Health Care Campus

Unknown

Rapid Profiling of Bone Marrow, at Presentation and After 5 Days of Induction Therapy

AML

Israel
Zhejiang University
Hangzhou Cheetah Cell Therapeutics Co., Ltd

Recruiting

NKG2D CAR-NK & r/rAML

AML

China
Beijing Immunochina Medical Science & Technology...

Not yet recruiting

Donor-derived CAR-T Cells in the Treatment of AML Patients

AML

China
Zhejiang University
Shanghai Zeke Biotechnology Co.，Ltd

Terminated

NK Cell Therapy for AML

AML

China
PETHEMA Foundation

Completed

Epidemiologic Registry PETHEMA LMA 2013

AML

Spain
Stichting Hemato-Oncologie voor Volwassenen Nederland

Recruiting

A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML (HO171)

AML, Adult

Netherlands
Therapeutic Advances in Childhood Leukemia Consortium
Bristol-Myers Squibb

Active, not recruiting

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

AML, Childhood

United States
Seattle Children's Hospital
Children's Healthcare of Atlanta; Pediatric Oncology Experimental Therapeutics...

Completed

POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients

AML | Acute Leukemia of Ambiguous Lineage | ALL | Relapsed/Refractory AML | Relapsed/Refractory ALL | Secondary AML/MDS

United States, Canada
Shanghai General Hospital, Shanghai Jiao Tong University...

Recruiting

CLL-1 CAR-NK Cells for Relapsed/Refractory AML

Relapsed Adult AML | Refractory AML

China
ETH Zurich
University of Zurich

Not yet recruiting

Pharmacoscopy-guided Clinical Standard-of-care in r/r AML (RAPID-01)

AML, Adult
Zhejiang University
Hangzhou Qihan Biotech Co.,Ltd.

Recruiting

Natural Killer(NK) Cell Therapy in r/r AML

AML, Adult

China
University of Birmingham

Completed

A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) (PARC)

Cancer | Pediatric ALL | Pediatric Solid Tumor | Pediatric AML

United Kingdom, Australia, Netherlands
Zhejiang University
Hangzhou Qihangene Biotech Co.,Ltd.

Recruiting

Natural Killer(NK) Cell Therapy Targeting CLL1 in Acute Myeloid Leukemia

AML, Adult

China
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Novel Approaches to Target MECOM/EVI1 in AML

AML, Adult

Italy
BioSight Ltd.

Recruiting

A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML

AML, Adult

United States
Apollomics Inc.
Zhejiang CrownMab Biotech Co. Ltd

Recruiting

Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients

Relapsed/Refractory AML

China
Fujian Medical University

Recruiting

Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML Patients

AML in Remission

China
Fujian Medical University

Unknown

CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)

Relapsed/Refractory AML

China
University Hospital, Grenoble
French Innovative Leukemia Organisation; BGMT

Completed

Treatment Outcome in Elderly Patients

AML | Elderly Patients

France
Apollomics Inc.
Zhejiang CrownMab Biotech Co. Ltd

Recruiting

Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML

Relapsed/Refractory AML

China
BioNova Pharmaceuticals (Shanghai) LTD.

Recruiting

A Study of BN104 in the Treatment of Acute Leukemia

AML, Adult | ALL, Adult

China
University of California, San Francisco

Completed

Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders

Lymphoma | Myeloproliferative Disorders | AML | Myelodysplasia | CML | ALL

United States
Clavis Pharma
Syneos Health; Theradex; CardiaBase; Learn & Confirm

Completed

The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055)

Relapsed/Refractory AML

United Kingdom, Spain
Chen Suning

Recruiting

Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML

Chemotherapy Effect | AML, Adult

China
Institute of Hematology & Blood Diseases Hospital

Unknown

Efficacy and Safety of Chidamide in CBF Leukemia

AML

China
The University of Hong Kong

Completed

Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD

AML | FLT3-ITD Mutation

Hong Kong
Samsung Medical Center
Ministry of Health, Republic of Korea

Recruiting

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Relapsed Pediatric AML | Refractory Pediatric AML | Relapsed Pediatric Solid Tumor | Refractory Pediatric Solid Tumor

Korea, Republic of
The First Hospital of Jilin University

Active, not recruiting

Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT

Relapsed Adult AML | Relapsed Adult ALL

China
Arog Pharmaceuticals, Inc.

Recruiting

Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Newly Diagnosed FLT3 Mutated AML

United States
Elucida Oncology
Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL)

Withdrawn

ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML (Pediatric AML)

Acute Myeloid Leukemia | AML, Childhood | Relapsed Pediatric AML | Refractory Pediatric AML
The University of Hong Kong

Recruiting

Oral Arsenic Trioxide for NPM1-mutated AML

NPMc+ AML

Hong Kong
Dana-Farber Cancer Institute
Karyopharm Therapeutics Inc; William Lawrence and Blanche Hughes Foundation

Active, not recruiting

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Relapsed Acute Lymphoblastic Leukemia (ALL) | Refractory Acute Lymphoblastic Leukemia (ALL) | Relapsed Acute Myelogenous Leukemia (AML) | Refractory Acute Myelogenous Leukemia (AML) | Relapsed Mixed Lineage Leukemia | Refractory Mixed Lineage Leukemia | Relapsed Biphenotypic Leukemia | Refractory... and other conditions

United States
Stichting Hemato-Oncologie voor Volwassenen Nederland
Swiss Group for Clinical Cancer Research

Active, not recruiting

Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients (HO155)

AML/MDS

Netherlands, Belgium, Germany, Switzerland

Clinical Trials on AML

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations